Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?

Med J Malaysia. 2020 Sep;75(5):591-593.

Abstract

A 67-year-old mental institute resident was treated for smear-positive pulmonary tuberculosis. His background history included chronic essential hypertension which was well-controlled with amlodipine 10mg daily. However, his blood pressure became suboptimal one week into antitubercular treatment, necessitating escalation of antihypertensive therapy up to six medications. Following completion of antitubercular treatment, his blood pressure improved markedly. The number of antihypertensives was able to be reduced to only two after a month. We postulate that rifampicin has attenuated the therapeutic effect of amlodipine via potent induction of hepatic CYP3A4 but the failure to control the blood pressure even with medications unrelated to cytochrome P450 pathways raises the spectre of an additional interaction.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amlodipine / pharmacology
  • Antibiotics, Antitubercular / adverse effects*
  • Antibiotics, Antitubercular / pharmacology*
  • Antihypertensive Agents / pharmacology*
  • Drug Interactions
  • Drug Therapy, Combination*
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Rifampin / adverse effects*
  • Rifampin / pharmacology*
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*

Substances

  • Antibiotics, Antitubercular
  • Antihypertensive Agents
  • Amlodipine
  • Rifampin